• Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46(3):922-38. [135 references]

This is the current release of the guideline.

This guideline updates a previous version: Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92:1081-1091.

The class of recommendations (I, II, IIa, IIb, III) and the levels of evidence (A–C) are defined at the end of the "Major Recommendations."

Diagnosis of Varices and Variceal Hemorrhage

1. Screening esophagogastroduodenoscopy (EGD) for the diagnosis of esophageal and gastric varices is recommended when the diagnosis of cirrhosis is made (Class IIa, Level C).
2. On EGD, esophageal varices should be graded as small or large (>5 mm) with the latter classification encompassing medium-sized varices when 3 grades are used (small, medium, large). The presence or absence of red signs (red wale marks or red spots) on varices should be noted (Class IIa, Level C).

Management Recommendations

Patients with Cirrhosis and No Varices

3. In patients with cirrhosis who do not have varices, nonselective beta-blockers cannot be recommended to prevent their development (Class III, Level B).
4. In patients who have compensated cirrhosis and no varices on the initial EGD, it should be repeated in 3 years (Class I, Level C). If there is evidence of hepatic decompensation, EGD should be done at that time and repeated annually (Class I, Level C).

Patients with Cirrhosis and Small Varices That Have Not Bled

5. In patients with cirrhosis and small varices that have not bled but have criteria for increased risk of hemorrhage (Child B/C [see Table 2 in the original guideline document for Child-Pugh classification of the severity of cirrhosis] or presence of red wale marks on varices), nonselective beta-blockers should be used for the prevention of first variceal hemorrhage (Class IIa, Level C).
6. In patients with cirrhosis and small varices that have not bled and have no criteria for increased risk of bleeding, beta-blockers can be used, although their long-term benefit has not been established (Class III, Level B).
7. In patients with small varices that have not bled and who are not receiving beta-blockers, EGD should be repeated in 2 years (Class I, Level C). If there is evidence of hepatic decompensation, EGD should be done at that time and repeated annually (Class I, Level C). In patients with small varices who receive beta-blockers, a follow-up EGD is not necessary.

Patients with Cirrhosis and Medium/Large Varices That Have Not Bled

8. In patients with medium/large varices that have not bled but have a high risk of hemorrhage (Child B/C [see Table 2 in the original guideline document] or variceal red wale markings on endoscopy), nonselective beta-blockers (propranolol or nadolol) or EVL may be recommended for the prevention of first variceal hemorrhage (Class I, Level A).
9. In patients with medium/large varices that have not bled and are not at the highest risk of hemorrhage (Child A patients [see Table 2 in the original guideline document] and no red signs), nonselective beta-blockers (propranolol, nadolol) are preferred and EVL should be considered in patients with contraindications or intolerance or non-compliance to beta-blockers (Class I, Level A).
10. If a patient is placed on a nonselective beta-blocker, it should be adjusted to the maximal tolerated dose; follow-up surveillance EGD is unnecessary. If a patient is treated with EVL, it should be repeated every 1-2 weeks until obliteration with the first surveillance EGD performed 1 to 3 months after obliteration and then every 6 to 12 months to check for variceal recurrence (Class I, Level C).
11. Nitrates (either alone or in combination with beta-blockers), shunt therapy, or sclerotherapy should not be used in the primary prophylaxis of variceal hemorrhage (Class III, Level A).

Patients with Cirrhosis and an Acute Episode of Variceal Hemorrhage

12. Acute gastrointestinal (GI) hemorrhage in a patient with cirrhosis is an emergency that requires prompt attention with intravascular volume support and blood transfusions, being careful to maintain a hemoglobin of ~8 g/dL (Class I, Level B).
13. Short-term (maximum 7 days) antibiotic prophylaxis should be instituted in any patient with cirrhosis and GI hemorrhage (Class I, Level A). Oral norfloxacin (400 mg twice a day [BID]) or intravenous ciprofloxacin (in patients in whom oral administration is not possible) is the recommended antibiotic (Class I, Level A). In patients with advanced cirrhosis intravenous ceftriaxone (1 g/day) may be preferable particularly in centers with a high prevalence of quinolone-resistant organisms (Class I, Level B).
14. Pharmacological therapy (somatostatin or its analogues octreotide and vapreotide; terlipressin) should be initiated as soon as variceal hemorrhage is suspected and continued for 3 to 5 days after diagnosis is confirmed (Class I, Level A).
15. EGD, performed within 12 hours, should be used to make the diagnosis and to treat variceal hemorrhage, either with EVL or sclerotherapy (Class I, Level A).
16. Transjugular intrahepatic portosystemic shunt (TIPS) is indicated in patients in whom hemorrhage from esophageal varices cannot be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy (Class I, Level C).
17. Balloon tamponade should be used as a temporizing measure (maximum 24 hours) in patients with uncontrollable bleeding for whom a more definitive therapy (e.g., TIPS or endoscopic therapy) is planned (Class I, Level B).

Gastric Varices

18. In patients who bleed from gastric fundal varices, endoscopic variceal obturation using tissue adhesives such as cyanoacrylate is preferred, where available. Otherwise, EVL is an option (Class I, Level B).
19. A TIPS should be considered in patients in whom hemorrhage from fundal varices cannot be controlled or in whom bleeding recurs despite combined pharmacological and endoscopic therapy (Class I, Level B).

Patients with Cirrhosis Who Have Recovered from Acute Variceal Hemorrhage

20. Patients with cirrhosis who survive an episode of active variceal hemorrhage should receive therapy to prevent recurrence of variceal hemorrhage (secondary prophylaxis) (Class I, Level A).
21. Combination of nonselective beta-blockers plus EVL is the best option for secondary prophylaxis of variceal hemorrhage (Class I, Level A).
22. The nonselective beta-blocker should be adjusted to the maximal tolerated dose. EVL should be repeated every 1-2 weeks until obliteration with the first surveillance EGD performed 1 to 3 months after obliteration and then every 6 to 12 months to check for variceal recurrence (Class I, Level C).
23. TIPS should be considered in patients who are Child A or B (see Table 2 in the original guideline document) who experience recurrent variceal hemorrhage despite combination pharmacological and endoscopic therapy. In centers where the expertise is available, surgical shunt can be considered in Child A patients (Class I, Level A).
24. Patients who are otherwise transplant candidates should be referred to a transplant center for evaluation (Class I, Level C).

Definitions:

Level of Evidence

Level A: Data derived from multiple randomized clinical trials or meta-analyses.

Level B: Data derived from a single randomized trial, or nonrandomized studies.

Level C: Only consensus opinion of experts, case studies, or standard-of-care.

Grading System for Recommendations

Class I: Conditions for which there is evidence and/or general agreement that a given diagnostic evaluation, procedure or treatment is beneficial, useful, and effective.

Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a diagnostic evaluation, procedure or treatment.

Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.

Class IIb: Usefulness/efficacy is less well established by evidence/opinion.

Class III: Conditions for which there is evidence and/or general agreement that a diagnostic evaluation/procedure/treatment is not useful/effective and in some cases may be harmful.

None provided

The type of supporting evidence is specifically stated for each recommendation (see "Major Recommendations" field).

• Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46(3):922-38. [135 references]

Not applicable: The guideline was not adapted from another source.

1997 (revised 2007 Sep)

American Association for the Study of Liver Diseases - Private Nonprofit Research Organization
American College of Gastroenterology - Medical Specialty Society

American Association for the Study of Liver Disease

Practice Guidelines Committee of the American Association for the Study of Liver Diseases

Practice Parameters Committee of the American College of Gastroenterology

Authors: Guadalupe Garcia-Tsao, Section of Digestive Diseases, Yale University School of Medicine and VACT Healthcare System, New Haven, CT; Arun J. Sanyal, Division of Gastroenterology, Virginia Commonwealth University Medical Center, Richmond , VA; Norman D. Grace, Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA; William Carey, Department of Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, OH

American Association for the Study of Liver Disease Practice Guidelines Committee: Margaret C. Shuhart, MD, MS (Committee Chair); Gary L. Davis, MD (Board Liaison); Kiran Bambha, MD; Andres Cardenas, MD, MMSc; Stanley M. Cohen, MD; Timothy J. Davern, MD; Steven L. Flamm, MD; Steven-Huy B. Han, MD; Charles D. Howell, MD; David R. Nelson, MD; K. Rajender Reddy, MD; Bruce A. Runyon, MD; John B. Wong, MD; Colina Yim, RN; and Nizar N. Zein, MD

American College of Gastroenterology Practice Parameters Committee: John Inadomi, MD, FACG (Committee Chair); Darren Baroni, MD; David Bernstein, MD, FACG; William Brugge, MD, FACG; Lin Chang, MD; William Chey, MD, FACG; John Cunningham, MD, FACG; Kenneth DeVault, MD, FACG; Steven Edmundowicz, MD; Ronnie Fass, MD, FACG; Kelvin Hornbuckle, MD; Costas Kefalas, MD, FACG; Timothy Koch, MD, FACG; Jenifer Lehrer, MD; Anthony Lembo, MD; John O'Brien, MD; John Papp, Sr., MD, MACG; Henry Parkman, MD, FACG; Albert Roach, PharmD, FACG; Richard Sampliner, MD, MACG; Amnon Sonnenberg, MD, MSc, FACG; Subbaramiah Sridhar, MD, FACG; Miguel Valdovinos, MD; John Vargo, MD, MPH, FACG; Marcelo Vela, MD; and Nizar Zein, MD

Potential conflict of interest: Nothing to report

This is the current release of the guideline.

This guideline updates a previous version: Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92:1081-1091.

None available

This summary was completed by ECRI Institute on September 18, 2007. The information was verified by the guideline developer on October 10, 2007. This summary was updated by ECRI Institute on July 28, 2008 following the U.S. Food and Drug Administration advisory on fluoroquinolone antimicrobial drugs.

This NGC summary is based on the original guideline, which is subject to the American Association for the Study of Liver Diseases' copyright restrictions.